Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Sotagliflozin in Healthy Subjects
NCT03802487Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sotagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Absolute Bioavailability at Day 8. Started Jan 2019; status: completed.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03802487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802487.